1088965-37-0 | Gsk-923295

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$43.00	$30.00
5mg	98%	in stock	$142.00	$99.00
10mg	98%	in stock	$235.00	$164.00
25mg	98%	in stock	$469.00	$328.00
50mg	98%	in stock	$810.00	$567.00

Description

• Catalog Number: AD76976
• Chemical Name: Gsk-923295
• CAS Number: 1088965-37-0
• Molecular Formula: C32H38ClN5O4
• Molecular Weight: 592.1282
• MDL Number: MFCD16038931
• SMILES: CN(CC(=O)NC[C@@H](NC(=O)c1ccc(c(c1)Cl)OC(C)C)Cc1ccc(cc1)c1nc2n(c1)cccc2[C@@H](O)C)C

Computed Properties

• Complexity: 870
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 42
• Hydrogen Bond Acceptor Count: 6
• Hydrogen Bond Donor Count: 3
• Rotatable Bond Count: 12
• XLogP3: 5

Upstream Synthesis Route

3-Chloro-N-{(1S)-2-[(N,N-dimethylglycyl)amino]-1-[(4-{8-[(1S)-1-hydroxyethyl]imidazo[1,2-a]pyridin-2-yl}phenyl)methyl]ethyl}-4-[(1-methylethyl)oxy]benzamide is a compound widely utilized in chemical synthesis processes. This complex molecule serves as a key building block in the creation of various pharmaceuticals, agrochemicals, and materials. Its unique structure and functional groups make it a versatile substance for designing and synthesizing new compounds with desired properties. The presence of a chloro group, secondary amine, hydroxyl group, and aromatic moieties provides ample opportunities for chemical modifications and derivatizations, allowing for the production of diverse chemical entities with tailored functions. In the realm of drug discovery and development, this compound plays a crucial role in the construction of biologically active molecules that target specific disease pathways or cellular mechanisms. Its strategic placement within a molecular framework enables efficient and precise synthetic manipulations, leading to the generation of valuable chemical entities with potential therapeutic applications.

Literature

• Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program.

  Pediatric blood & cancer 20120601

• First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer.

  Cancer chemotherapy and pharmacology 20120301